NCT05596409 2026-04-22
ELCIN
Stemline Therapeutics, Inc.
Phase 2 Active not recruiting
Clinical Trials
14 trialsNCT07467772 2026-04-21
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06120283 2026-04-15
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06638307 2026-04-13
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Stemline Therapeutics, Inc.
Phase 1 Recruiting
NCT07198724 2026-04-09
ERADICATE
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT05386108 2026-04-06
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06382948 2026-04-03
ADELA
MedSIR
Phase 3 Recruiting
NCT04791384 2026-03-31
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
Criterium, Inc.
Phase 1/2 Terminated
NCT06492616 2026-03-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3 Recruiting
NCT06923527 2026-03-27
Circulating Tumor DNA
Yale University
Phase 2 Recruiting
NCT05573126 2026-03-20
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ellipses Pharma
Phase 1/2 Recruiting
NCT07209449 2026-03-18
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06075953 2026-03-16
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT07395336 2026-02-09
COMBINE-01
European Institute of Oncology
Phase 2 Not yet recruiting